Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up-Reference-Cited by-同舟云学术

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Published:2011-11 Issue:12 Volume:12 Page:1101-1108
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Regan Meredith M,Neven Patrick,Giobbie-Hurder Anita,Goldhirsch Aron,Ejlertsen Bent,Mauriac Louis,Forbes John F,Smith Ian,Láng István,Wardley Andrew,Rabaglio Manuela,Price Karen N,Gelber Richard D,Coates Alan S,Thürlimann Beat

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer;Burstein;J Clin Oncol,2010

2. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer;N Engl J Med,2005

3. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98;Coates;J Clin Oncol,2007

4. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer;N Engl J Med,2009

5. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study;Colleoni;J Clin Oncol,2011

Cited by 350 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence, Timing, and Long-Term Outcomes of COVID-19 Vaccine-Related Lymphadenopathy on Screening Mammography;Journal of the American College of Radiology;2024-09

2. Targeting estrogen mediated CYP4F2/CYP4F11-20-HETE metabolic disorder decelerates tumorigenesis in ER+ breast cancer;Biochemistry and Biophysics Reports;2024-07

3. Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments;PharmacoEconomics;2024-04-01

4. Ribociclib plus Endocrine Therapy in Early Breast Cancer;New England Journal of Medicine;2024-03-21

5. Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism;Journal of Nanobiotechnology;2024-03-19